Pitrakinra - Aerovance
Alternative Names: AER-001; Aeroderm; Aerovant; BAY-16-9996; non-PEGylated AER-001; non-PEGylated pitrakinraLatest Information Update: 19 Jun 2015
At a glance
- Originator Bayer
- Developer Aerovance; Bayer
- Class Antiasthmatics
- Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute asthma; Allergic asthma; Asthma; Atopic dermatitis
Most Recent Events
- 08 Jun 2010 Aerovance shares phase IIb data with potential partners
- 08 Jun 2010 Top-line efficacy and adverse events data from the phase IIb AeroTrial trial in asthma released by Aerovance
- 03 Nov 2009 Aerovance completes enrolment in the phase IIb AeroTrial for Asthma in USA, UK, Hungary & Poland (NCT00801853)